Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial.

Chest · 2022 · PMC10835052 · PMID 34543665

Europe PMC DOI

hedged sentences

0.1900

closest p · 3.8× alpha

0.1900

boldest claim

The sentences

did not reach statistical significanceP = .19not close (p > 0.1)

Regarding subjective sleepiness, four of five patients with an ESS score > 6 at baseline experienced improvement in the score, from 11 [3-12.5] to 6 [1.5-6.5], although this did not reach statistical significance ( P = .19).

also in 111,027 other papers

showed a trendno p-value reported

Given that the combination showed a trend for reduction in sleepiness in patients with an ESS score > 6, future studies in sleepier patients should be considered.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.